Elasmogen’s CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here. Dr. Caroline Barelle: A Leader in Biotechnology Driving Innovation in Biologics Drug Development
Year: 2019
Elasmogen CEO Caroline Barelle named one of top 20 women in leading biotech roles in Europe | 21.05.2019
Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in leading biotech roles in Europe. The full article can be found at https://labiotech.eu/tops/women-leaders-biotech-europe/ -ENDS-
Elasmogen CEO shortlisted for BBSRC Innovator of the Year 2019 award | 01.05.2019
Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the Year award include our CEO, Dr Caroline Barelle. The BBSRC Innovator of the Year award recognises the full breadth of impacts that BBSRC investments in research have on lives, society and the economy. It celebrates the individuals and small teams who have […]
Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting | 20.03.2019
Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen a biotech company developing next generation therapeutic biologics, today announced they will present a poster on their VNAR-based protein drug conjugates research targeting ROR1 at the upcoming American Association […]
Elasmogen CEO Caroline Barelle Interviewed by Life Sciences Scotland for Leadership Insight | 30.01.2019
Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of their Insight series. The article can be accessed here.
Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge | 07.01.2019
Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019: Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets. ImmunoForge will be responsible […]